420 related articles for article (PubMed ID: 32648580)
1. Prognostic and immune regulating roles of YIF1B in Pan-Cancer: a potential target for both survival and therapy response evaluation.
Liu J; Chen Z; Zhao P; Li W
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32648580
[TBL] [Abstract][Full Text] [Related]
2. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
3. A Comprehensive Prognostic and Immune Analysis of SLC41A3 in Pan-Cancer.
Liu J; Zhang S; Dai W; Xie C; Li JC
Front Oncol; 2020; 10():586414. PubMed ID: 33520701
[TBL] [Abstract][Full Text] [Related]
4. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value and immunological role of PDCD1 gene in pan-cancer.
Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D
Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926
[TBL] [Abstract][Full Text] [Related]
6. Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study.
Liu JN; Kong XS; Huang T; Wang R; Li W; Chen QF
Front Immunol; 2020; 11():2048. PubMed ID: 33072070
[TBL] [Abstract][Full Text] [Related]
7. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the Expression and Prognostic Value of MSH2 in Pan-Cancer Based on Bioinformatics.
Qiu W; Ding K; Liao L; Ling Y; Luo X; Wang J
Biomed Res Int; 2021; 2021():9485273. PubMed ID: 34859104
[TBL] [Abstract][Full Text] [Related]
9. The prognostic and immunological effects of ZBTB7C across cancers: friend or foe?
Chen X; Jiang Z; Wang Z; Jiang Z
Aging (Albany NY); 2021 May; 13(9):12849-12864. PubMed ID: 33946045
[TBL] [Abstract][Full Text] [Related]
10. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
Lv J; Zhu Y; Ji A; Zhang Q; Liao G
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
[TBL] [Abstract][Full Text] [Related]
11. Pan-Cancer Analysis Revealed
Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer.
Xiao C; Yang L; Jin L; Lin W; Zhang F; Huang S; Huang Z
Front Genet; 2022; 13():962028. PubMed ID: 36061184
[No Abstract] [Full Text] [Related]
13. Pan-Cancer Integrated Analysis of HSF2 Expression, Prognostic Value and Potential Implications for Cancer Immunity.
Chen F; Fan Y; Liu X; Zhang J; Shang Y; Zhang B; Liu B; Hou J; Cao P; Tan K
Front Mol Biosci; 2021; 8():789703. PubMed ID: 35087869
[TBL] [Abstract][Full Text] [Related]
14. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer.
Wu J; Yu X; Zhu H; Chen P; Liu T; Yin R; Qiang Y; Xu L
Front Mol Biosci; 2023; 10():1178446. PubMed ID: 37388242
[No Abstract] [Full Text] [Related]
15. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and immunological role of Ras-related protein Rap1b in pan-cancer.
Cui G; Wang C; Lin Z; Feng X; Wei M; Miao Z; Sun Z; Wei F
Bioengineered; 2021 Dec; 12(1):4828-4840. PubMed ID: 34346294
[TBL] [Abstract][Full Text] [Related]
17. BRCA1-Associated Protein Is a Potential Prognostic Biomarker and Is Correlated With Immune Infiltration in Liver Hepatocellular Carcinoma: A Pan-Cancer Analysis.
Ju Q; Li XM; Zhang H; Zhao YJ
Front Mol Biosci; 2020; 7():573619. PubMed ID: 33240929
[TBL] [Abstract][Full Text] [Related]
18. Pan-Cancer Analysis Reveals the Multidimensional Expression and Prognostic and Immunologic Roles of
Zhang S; Xiong H; Yang J; Yuan X
Front Mol Biosci; 2021; 8():792154. PubMed ID: 35155565
[TBL] [Abstract][Full Text] [Related]
19. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
20. Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker.
Zhang R; Wang W; Zhang N; Chen X; Liu W; Zhang L; Liu N
J Cell Mol Med; 2022 Sep; 26(18):4859-4871. PubMed ID: 35989423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
